Prognostic Value of Natriuretic Peptides in Chagas’ Disease: A 3-Year Follow-Up Investigation
Authors:
- Silvia Heringer-WaltherSHSilvia Heringer-Walther
- Niels WesselNiels Wessel
- Tiago Moreira VenturaTVTiago Moreira Ventura
- Yong WangYWYong Wang
- Heinz-Peter SchultheissHSHeinz-Peter Schultheiss
- Thomas WaltherTWThomas Walther
- 12 December 2007
- journal article
- Published by S. Karger AG in Cardiology
- Vol. 110 (4) , 217-225
Abstract
Background: Chagas’ disease (CD) affects around 18 million people in Latin America. To determine the diagnostic and prognostic value of natriuretic peptides in patients with CD, we measured atrial (ANP) and brain natriuretic peptide (BNP), and compared the findings with other dilated cardiomyopathies (DCM). Methods: Blood samples were obtained from 111 CD patients, 62 patients with DCM due to other causes, and 43 gender- and age-matched healthy subjects. The CD and DCM patients were subdivided according to their NYHA classification. Natriuretic peptide concentrations were determined by immunoradiometric assays. Results: ANP and more pronounced BNP levels were increased in CD and DCM patients in relation to the NYHA class. Circulating BNP concentrations were higher in CD patients in NYHA classes I–II than in the corresponding DCM patients (p = 0.020). Importantly, ANP and BNP were already significantly elevated in CD patients without systolic ventricular dysfunction (p ≤ 0.001). In CD patients, both peptides were highly correlated with echocardiographic parameters (p < 10–14). Both ANP and BNP had comparable ability to predict death or the necessity for heart transplant (p < 0.0001). Conclusion: Natriuretic peptide levels can be used as a marker of asymptomatic CD without ventricular dysfunction and thus could be an ideal tool to identify these patients for early therapy.Keywords
This publication has 26 references indexed in Scilit:
- Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMETEuropean Heart Journal, 2005
- Brain natriuretic peptide predicts survival in Chagas' disease more effectively than atrial natriuretic peptideHeart, 2005
- Clinical applications of B-type natriuretic peptide (BNP) testingEuropean Heart Journal, 2003
- AT1 receptor blockade increases cardiac bradykinin via neutral endopeptidase after induction of myocardial infarction in ratsThe FASEB Journal, 2002
- Atrial natriuretic factor as marker of myocardial compromise in Chagas' diseaseRegulatory Peptides, 2002
- The Prognostic Value of B-Type Natriuretic Peptide in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2001
- Behavior of Atrial Natriuretic Factor in an Experimental Model of Trypanosoma cruzi Infection in RatsJournal of Parasitology, 2001
- Brain natriuretic peptide appears to act locally as an antifibrotic factor in the heartCanadian Journal of Physiology and Pharmacology, 2001
- Pathophysiological insights into the cardiomyopathy of Chagas' disease.Circulation, 1990
- Chagas' DiseaseCirculation, 1956